However, Schuhmann et al. showed that depleting B-cells pharmacologically using anti-CD20 24 h before the MCAO in mice or using B-cell-deficient JHD−/− mice that do not have circulating B-cells did not affect the stroke lesion size, number of neutrophils and monocytes, and levels of TNF-α and IL-1β at day 1 and 3 post-MCAO [181]. The gene discussed is IL1B; the disease is stroke disorder.